ETF Holdings Breakdown of ARWR

Stock NameArrowhead Pharmaceuticals Inc
TickerARWR(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS04280A1007
LEI549300O3CSB8T7OZ3D66

News associated with ARWR

Assenagon Asset Management S.A. Has $289,000 Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Assenagon Asset Management S.A. trimmed its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 57.2% during the first quarter, HoldingsChannel reports. The institutional investor owned 22,701 shares of the biotechnology company’s stock after selling 30,312 shares during the period. Assenagon Asset Management S.A.’s holdings in Arrowhead Pharmaceuticals were worth $289,000 at […] - 2025-06-20 07:52:52
Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $43.71
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year […] - 2025-06-13 05:55:10
California State Teachers Retirement System Lowers Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
California State Teachers Retirement System trimmed its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 1.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 105,154 shares of the biotechnology company’s stock after selling 1,139 shares during the quarter. California State Teachers Retirement System’s holdings in Arrowhead Pharmaceuticals were worth $1,977,000 at […] - 2025-06-08 08:49:07
Mackenzie Financial Corp Buys New Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Mackenzie Financial Corp acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 7,299 shares of the biotechnology company’s stock, valued at approximately $137,000. Other large investors also recently modified their holdings of the company. Raymond James Financial Inc. bought a new […] - 2025-06-06 07:49:00
Squarepoint Ops LLC Has $1.62 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Squarepoint Ops LLC reduced its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 55.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 86,044 shares of the biotechnology company’s stock after selling 107,750 shares during the quarter. Squarepoint Ops […] - 2025-05-30 09:08:58
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Tidal Investments LLC
Tidal Investments LLC lowered its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 4.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,249 shares of the biotechnology company’s stock after selling 1,062 shares during the period. Tidal Investments LLC’s holdings in Arrowhead Pharmaceuticals were […] - 2025-05-30 08:25:01
Millennium Management LLC Acquires 268,946 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Millennium Management LLC lifted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 41.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 914,550 shares of the biotechnology company’s stock after acquiring an additional 268,946 shares during the period. Millennium […] - 2025-05-22 08:01:01
HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $80.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 422.53% from the company’s current price. […] - 2025-05-22 05:58:43
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Raised to “Hold” at StockNews.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Several other equities analysts have also recently commented on the stock. B. Riley restated a “buy” rating and set a $38.00 price target (down from $51.00) on […] - 2025-05-16 08:46:55
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Comerica Bank
Comerica Bank reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 5.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,921 shares of the biotechnology company’s stock after selling 2,259 shares during the quarter. Comerica Bank’s holdings […] - 2025-05-15 08:08:52
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $60.00 price objective on the biotechnology company’s stock. Several other research firms have also recently commented on ARWR. B. Riley reissued a “buy” rating and set a $38.00 […] - 2025-05-14 07:58:52
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Cut to $17.00 by Analysts at Citigroup
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price reduced by Citigroup from $21.00 to $17.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a neutral rating on the biotechnology company’s stock. Several other equities research analysts also recently commented on the company. B. Riley restated a “buy” rating and […] - 2025-05-14 07:58:48
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up After Strong Earnings
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $13.97, but opened at $15.75. Arrowhead Pharmaceuticals shares last traded at $15.56, with a volume of 844,732 shares trading hands. The biotechnology company reported $2.75 […] - 2025-05-14 05:40:47
Northern Trust Corp Purchases 151,654 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Northern Trust Corp raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 11.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,484,419 shares of the biotechnology company’s stock after buying an additional 151,654 shares during the period. Northern Trust Corp’s holdings in Arrowhead Pharmaceuticals were worth $27,907,000 at the end […] - 2025-05-12 08:36:56
Voya Investment Management LLC Sells 246,573 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Voya Investment Management LLC trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 82.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 53,793 shares of the biotechnology company’s stock after selling 246,573 shares during the period. Voya Investment Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,011,000 as of its […] - 2025-05-07 08:57:00
Bank of Montreal Can Boosts Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Bank of Montreal Can grew its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 13.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,018 shares of the biotechnology company’s stock after purchasing an additional 1,759 shares […] - 2025-04-25 07:36:52
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $41.44 Consensus Target Price from Analysts
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year […] - 2025-04-24 05:28:50
Arrowhead Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired 7,512 put options on the stock. This is an increase of approximately 1,016% compared to the typical daily volume of 673 put options. Analyst Upgrades and Downgrades A number of analysts recently issued reports on the company. […] - 2025-04-23 05:50:52
Legal & General Group Plc Cuts Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Legal & General Group Plc reduced its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 3.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 245,272 shares of the biotechnology company’s stock after selling 9,369 shares during the […] - 2025-04-22 07:47:17
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Russell Investments Group Ltd.
Russell Investments Group Ltd. decreased its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 41.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 183,289 shares of the biotechnology company’s stock after selling 132,084 shares during the quarter. Russell Investments Group Ltd.’s […] - 2025-04-17 08:54:50
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stake Cut by Fmr LLC
Fmr LLC decreased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 15.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,101,083 shares of the biotechnology company’s stock after selling 966,486 shares during the period. Fmr […] - 2025-04-16 07:34:56
Geode Capital Management LLC Sells 9,172 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Geode Capital Management LLC lessened its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 0.3% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,954,947 shares of the biotechnology company’s stock after selling 9,172 shares during the period. Geode Capital Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $55,566,000 as […] - 2025-04-14 08:43:00
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Schroder Investment Management Group
Schroder Investment Management Group decreased its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 1.2% during the 4th quarter, HoldingsChannel reports. The fund owned 206,070 shares of the biotechnology company’s stock after selling 2,490 shares during the quarter. Schroder Investment Management Group’s holdings in Arrowhead Pharmaceuticals were worth $3,835,000 as of its most […] - 2025-04-06 09:32:58
Corebridge Financial Inc. Sells 10,761 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Corebridge Financial Inc. lowered its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 199,154 shares of the biotechnology company’s stock after selling 10,761 shares during the period. Corebridge […] - 2025-03-31 08:22:49
11,172 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Purchased by Cibc World Markets Corp
Cibc World Markets Corp acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,172 shares of the biotechnology company’s stock, valued at approximately $210,000. Several other institutional investors have also […] - 2025-03-27 08:54:57
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of “Moderate Buy” from Brokerages
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average […] - 2025-03-27 06:38:50
Swiss National Bank Has $4.14 Million Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Swiss National Bank grew its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 0.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 220,000 shares of the biotechnology company’s stock after buying an additional 1,700 shares during the quarter. Swiss […] - 2025-03-26 07:44:45
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stake Cut by US Bancorp DE
US Bancorp DE cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 14.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 34,522 shares of the biotechnology company’s stock after selling 5,601 shares during the period. US Bancorp DE’s holdings in Arrowhead Pharmaceuticals were worth $649,000 as of its most […] - 2025-03-12 08:43:02
Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $41.44
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price […] - 2025-03-05 06:20:53
Rhumbline Advisers Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Rhumbline Advisers raised its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 380,344 shares of the biotechnology company’s stock after buying an additional 7,912 shares during the period. Rhumbline […] - 2025-02-26 08:19:02

ARWR institutional holdings

The following institutional investment holdings of ARWR have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 74,307USD 1,194,113 2.6%
2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 53,999USD 867,764
2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 68,917USD 1,107,496
2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 68,917USD 1,107,496
2025-06-26 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 1,793USD 28,814
Total =267,933 USD 4,305,683
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.